Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ovarian cancer
Biotech
ESMO: Lilly ADC sees 79% ORR in competitive ovarian cancer space
The phase 1 data shed light on Lilly's chances of competing for a market targeted by rivals including AbbVie and Genmab.
Nick Paul Taylor
Oct 24, 2026 2:30am
ESMO: GSK cancer R&D chief says data ‘reinforces belief’ in mo-rez
Oct 23, 2026 6:05pm
ESMO: Why Zentalis is already dreaming of launching WEE1 drug
Oct 23, 2026 10:15am
Genmab ph. 2 data spur claim ADC ‘clearly superior’ to Elahere
Oct 5, 2026 4:14am
ASCO: Tubulis touts ovarian cancer data that attracted Gilead
May 30, 2026 9:36am
OSE turns up the heat on ovarian cancer with phase 2 win
May 22, 2026 7:14am